Ductal carcinoma in situ (DCIS)
Breast cancer cells confined inside the milk ducts, found mostly by mammography as calcifications. It is not life-threatening in itself, but around a third would progress to invasive cancer if left.
DCIS makes up 20-25% of screen-detected breast cancers. Standard treatment is lumpectomy with radiotherapy (or mastectomy for extensive disease) plus tamoxifen or an aromatase inhibitor if ER-positive; low-dose tamoxifen (5 mg, TAM-01) halves recurrence with fewer side effects. Because many DCIS lesions are indolent, active surveillance trials (COMET, LORIS, LORD) tested omitting surgery for low-risk disease, and COMET found no excess invasive cancer at 2 years. It is a leading example of the overdiagnosis debate in screening.
Pages like this
not linked directly; found by shared links- TrialProtecT
Shares Active surveillance and observation, Active surveillance.
- TermMGUS and smouldering myeloma
Shares Active surveillance and observation, Active surveillance.
- TermMastectomy
Shares Lumpectomy (breast-conserving surgery), HR-positive / HER2-negative breast cancer.
- TermGleason score and Grade Group
Shares Active surveillance and observation, Active surveillance.
- TrialSANO
Shares Active surveillance and observation, Active surveillance.
- TechnologySoy foods and breast cancer
Shares Tamoxifen, HR-positive / HER2-negative breast cancer.
- PersonBernard Fisher
Shares Tamoxifen, HR-positive / HER2-negative breast cancer.
- Key paperIBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years
Shares Tamoxifen, HR-positive / HER2-negative breast cancer.